254 related articles for article (PubMed ID: 29948762)
1. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Zeta LM
Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
[TBL] [Abstract][Full Text] [Related]
3. National needs assessment of patients treated at the United States Federally-Funded Hemophilia Treatment Centers.
Butler RB; Cheadle A; Aschman DJ; Riske B; Senter S; McLaughlin KM; Young G; Ahuja S; Forsberg AD
Haemophilia; 2016 Jan; 22(1):e11-7. PubMed ID: 26517156
[TBL] [Abstract][Full Text] [Related]
4. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
5. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Clark BL; Hou J; Chou CH; Huang ES; Conti R
Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
[TBL] [Abstract][Full Text] [Related]
6. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
Shi L; Wharton MK; Monnette A
Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
[TBL] [Abstract][Full Text] [Related]
7. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
8. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Conti RM; Bach PB
Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a comprehensive pharmaceutical care program for an underserved population.
Mascardo LA; Spading KA; Abramowitz PW
Am J Health Syst Pharm; 2012 Jul; 69(14):1225-30. PubMed ID: 22761077
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive care for hemophilia and related inherited bleeding disorders: why it matters.
Hoots WK
Curr Hematol Rep; 2003 Sep; 2(5):395-401. PubMed ID: 12932311
[TBL] [Abstract][Full Text] [Related]
11. Implementation of a $4 generic drug program in a 340B pharmacy.
Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia Management via Data Collection and Reporting: Initial Findings from the Comprehensive Care Sustainability Collaborative.
Tarantino MD; Pindolia VK
J Manag Care Spec Pharm; 2017 Jan; 23(1):51-56. PubMed ID: 28025929
[TBL] [Abstract][Full Text] [Related]
13. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS)
Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
[TBL] [Abstract][Full Text] [Related]
14. Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T; Williams C; Vranek K; Mattingly TJ
Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
[TBL] [Abstract][Full Text] [Related]
15. A comparison of medication access services at 340B and non-340B hospitals.
Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
[TBL] [Abstract][Full Text] [Related]
16. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
Ruley M; Belcher M; Sayre H; Coustasse A
Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
[TBL] [Abstract][Full Text] [Related]
17. Challenges for Managed Care from 340B Contract Pharmacies.
Fein AJ
J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.
Schieve LA; Byams VR; Dupervil B; Oakley MA; Miller CH; Soucie JM; Abe K; Bean CJ; Hooper WC
MMWR Surveill Summ; 2020 Sep; 69(5):1-18. PubMed ID: 32881847
[TBL] [Abstract][Full Text] [Related]
19. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
20. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
